Oppenheimer suggests that Whitehawk Therapeutics' antibody drug conjugates demonstrate potential effectiveness against cancer. The report also include...
Bullish
Whitehawk Therapeutics presented comprehensive preclinical data for its next-generation Antibody Drug Conjugate (ADC) portfolio, including HWK-007, HW...
Neutral
Whitehawk Therapeutics CEO David James Lennon recently sold 14,500 shares of common stock for a total of $49,010 to cover tax withholding obligations....